Hodgkin Lymphoma Trial Results
Drug Slows Progression of Cutaneous T-Cell Lymphoma
(Posted: 03/31/2010) - Patients with cutaneous T-cell lymphoma who received the drug denileukin diftitox survived without disease progression for a median of more than 2 years, compared with just over 4 months for patients who received a placebo, according to a study published March 8, 2010, in the Journal of Clinical Oncology.
PET Can Strongly Predict Likelihood of Early Relapse in Hodgkin Lymphoma
(Posted: 08/10/2007) - A positron emission tomography (PET) scan taken after two cycles of standard chemotherapy in patients with advanced Hodgkin lymphoma was able to predict with 92-percent accuracy how effective a complete course of the chemotherapy would be, according to a report published July 23, 2007 as an early release online publication of the August 20, 2007, issue of the Journal of Clinical Oncology.
(Posted: 03/31/2010) - Patients with cutaneous T-cell lymphoma who received the drug denileukin diftitox survived without disease progression for a median of more than 2 years, compared with just over 4 months for patients who received a placebo, according to a study published March 8, 2010, in the Journal of Clinical Oncology.
PET Can Strongly Predict Likelihood of Early Relapse in Hodgkin Lymphoma
(Posted: 08/10/2007) - A positron emission tomography (PET) scan taken after two cycles of standard chemotherapy in patients with advanced Hodgkin lymphoma was able to predict with 92-percent accuracy how effective a complete course of the chemotherapy would be, according to a report published July 23, 2007 as an early release online publication of the August 20, 2007, issue of the Journal of Clinical Oncology.
